

7. Literaturverzeichnis

(1) Newman, P: Platelet alloantigens: cardiovascular as well as immunological risk factor? Lancet 349 (1997), 370-371.

(2) Walter, D, V Schachinger, M Elsner, S Dimmler, AM Zeiher: Platelet gp IIIa polymorphism and risk factor of coronary stent thrombosis. Lancet (1997), 1217-1219.

(3) Ridker, PM, CH Hennekens, C Schmitz, MJ Stampfer, K Lindpainter: $PI^{A1/A2}$ Polymorphism of platelet gp IIIa and risk of myocardial infarction, stroke and venous thrombosis. Lancet 349 (1997), 385-388.

(4) Neumann FJ, Gawaz, A Schömig: Glykoproteine der Thrombozytenmembran als Angriffspunkt für Pharmakologische Interventionen in der Therapie der KHK. Dtsch med Wsch 122 (1997), 1224 - 1230.

(5) Weiss EJ, PF Bray, M Tayback, et al: A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N. Engl J Med 334 (1996), 1090-94.

(6) Carter AM, N Ossei-Gerning, PJ Grant: Platelet glycoprotein IIIa polymorphism in young men with myocardial infarction. Lancet 348 (1996), 485-486.

(7) Carter AM, N Ossei-Gerning, PJ Grant: Platelet glycoprotein IIIa PI^A polymorphism and myocardial infarction. N Engl J Med 335 (1996), 1072-73.

(8) Marian AJ, R Burgada, NS Kleinman: Platelet glycoprotein IIIa PI^A polymorphism and myocardial infarction. N Engl J Med 335 (1996), 1071-1072.

(9) Osborn SV, KK Hampton, D Smillie, KS Channer, ME Daly: Platelet glycoprotein IIIa gene polymorphism and myocardial infarction. Lancet 348 (1996), 1309-10.

(10) Odawara M, Matsunuma A Yamashita K: Platelet Glycoprotein IIIa PIA polymorphism and Japanese diabetic patients with coronary heart disease. *Lancet* 348 (1996), 1310.

(11) Gawaz, M, FJ Neumann, I Ott, A May, S Rüdiger, A Schöming: Platelet function in acute myocardial infarction treated by direct angioplasty. *Circulation* 93 (1996), 229 - 237.

(12) Neumann, FJ, N Marx, M Gawaz, K Brand, I Ott ,C Rokitta, C Sticherling, C Meinel, A May, A Schöming: Neutrophil and platelet activation during passage across the balloon injured coronary artery segment in patients undergoing angioplasty. *J Am Coll Cardiol* 27 (1996), 819-824.

(13) Fischmann, DL, DS Leon: Baim for the STRESS investigators: A randomised comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery Disease. *N Engl J Med* 331 (1994), 496-501.

(14) Ivanhoe, RJ, WS Weintraub, JS Douglas: Percutaneous transluminal coronary angioplasty of chronic total occlusions. Primary success, Restenosis and long-term clinical follow-up. *Circulation* 85 (1992), 106-115.

(15) Serruys, PW, P de Jaegere, F Kiemeneij for the BENESTENT Study Group: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patient with coronary artery disease. *N Engl J Med* 331 (1994), 489-495.

(16) Sirnes, PA, S Golf, Y Myreng, P Molstad, H Emanuelsson, P Albertson, M Brekke, A Mangschau: Stenting in a chronic coronary occlusion (SICCO): A randomised, controlled trial of adding stent implantation after successful angioplasty. *J Amer Coll Cardiol* 28 (1996), 1444-1451.

(17) Davies, MJ: The composition of coronary artery plaques. *N Engl J Med* 336 (1997), 1312-1314.

(18) Carrozza JP Jr, Schatz RA, George CJ, Leon MB, King SB 3rd, Hirshfeld JW, Curry RC Jr, Ivanhoe RJ, Buchbinder M, Cleman MW, Goldberg S, Ricci D, Popma JJ, Safian RD, Baim DS: Acute and long-term outcome after Palmaz-Schatz stenting: analysis from the New Approaches to Coronary Intervention (NACI) registry. *Am J Cardiol* 1997 Nov 20;80(10A):78K-88K

(19) Fischmann, DL, M Savage, S Goldberg: Coronary stent placement in patients with de-novo and restenotic native coronary artery lesions. *Coronary Art Disease* 5 (1994), 571-574.

(20) Nunes, G, I Pinto, L Mattos, F Ferres, A Chaves, L Tanajura, M Centemero, AC Sousa, JE Sousa: Coronary stent implantation in vessels smaller than 3 mm is associated with higher Restenosis rates. *Eur Heart J* 17 (1996), Suppl I, 173.

(21) Shulman, NR, VJ Mader, MC Hiller , EM Collier: Platelet and leukocyte isoantigen and their antibodies: serologic, physiologic and clinical studies. *Prog Haematol* 4 (1964), 222-304.

(22) Schumacher B, P Pecher, BU von Specht, T Stegmann: Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. *Circulation* 97 (1998), 645-50 .

(23) Gleichmann U, Mannebach H, Lichtlen P: Erster Bericht über die Struktur und Leistungsfähigkeit der Herzkatheterlabors in der Bundesrepublik Deutschland. Umfrage der Kommission für klinische Kardiologie der Deutschen Gesellschaft für Herz- und Kreislaufforschung über die Jahre 1979 bis 1981. *Z Kardiol* 74 (1981), 489-493.

(24) Gleichmann U, Mannebach H, Lichtlen P: Elfter Bericht über die Struktur und Leistungsfähigkeit der Herzkatheterlabors in der Bundesrepublik Deutschland.

Umfrage der Kommission für Klinische Kardiologie der Deutschen Gesellschaft für Herz- und Kreislaufforschung über das Jahr 1995. *Z Kardiol* 85 (1995), 973-976.

(25) Statistisches Jahrbuch für die Bundesrepublik Deutschland. Statistisches Bundesamt (Hrsg) (1993) Metzler-Poeschel, Wiesbaden 1993.

(26) Kuulasmaa, K, H Tunstall-Pedoe, A Dobson, S Fortmann, S Sans, H Tolonen, A Evans, M Ferrario, J Tuomiletho for the WHO MONICA-Project: Estimation of contribution of changes in risk factors in coronary-event rates across the WHO MONICA Project populations. *Lancet* 355 (2000), 675-687.

(27) Nijhoff, M: Quantitative coronary and left ventricular cineangiography by Reiber JHC, Serruys PW, Seager CJ (1986).

(28) Serruys, PW, HE Luijten, KJ Beatt, R Geuskens, P de Feyter, W van den Brandt: Incidence of Restenosis after successful coronary angioplast. A time-related phenomenon. *Circulation* 77 (1988), 361-371.

(29) Horie, H, M Takahasi, M Izumi, A Fujita, T Sakamoto, O Kito, H Okamura, M Kinoshita: Association of an acute reduction in Lipoprotein (a) with coronary artery Restenosis after percutaneous transluminal coronary angioplasty. *Circulation* 96 (1997), 166-173.

(30) Montalescot, G, A Ankri, E Vicaut, G Drobinski, Y Grosogeat, D Thomas: Fibrinogen after coronary angioplasty as a risk factor. *Circulation* 92 (1995), 31-38.

(31) Van Belle, E, C Bateurs, E Hubert: Restenosis rates in diabetic patients. A comparison of coronary Stenting and balloon and balloon angioplasty in native coronary vessels. *Circulation* 96 (1997), 1454-1460.

(32) Reifart N, M Vandormael, M Krajcar, S Göhring, W Preusler, F Schwarz, H Ströger, M Hofmann, J Klöpfer, S Müller, J Haase: Randomised comparison of

angioplasty of complex coronary lesions at a single center. Excimer laser, rotational atherectomy and balloon angioplasty comparison (ERBAC) Study. *Circulation* 96 (1997), 91-98.

(33) Karbatsch, T, B Hempel, J Hofmeister, E Lieback, R Hetzer: TMLR - Erste Erfahrungen in der Therapie der diffusen koronaren Herzerkrankung. In Müller & Berlien (Hrsg): *Transmyocardiale Laser-Revaskularisation. Stand und Ausblicke* (Ecomed: Berlin 1995), 53-64.

(34) Condado, JA, R Waksman, O Gurdiel, R Espinosa, J Gonzalez, B Burger, G Villoria, H Aquatella, IR Crocker, KB Seng, SF Liprie: Long-term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans. *Circulation* 96 (1997), 727-732.

(35) Teirstein, PS, V Massulo, S Jani: Catheter-based radiotherapy to inhibit Restenosis after coronary Stenting. *N Engl J Med* 336 (1997) , 1697- 1703.

(36) Danesh, JR, R Collnis: Chronic infection and coronary heart disease. Is there a link? *Lancet* 350 (1997), 430-436.

(37) Saikku, P, K Mattila, MS Nieminen, JK Huttunen, M Leinonen, MR Ekman, PH Mäkel, V Valtonen: Serological evidence of an association of novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. *Lancet* II (1988), 983-986.

(38) Zhou, YF, MB Leon, MA Waclawiw, JJ Popma, ZX Yu, T Finkel, SE Epelstein: Association between prior cytomegalovirus infection and the risk of Restenosis after coronary atherectomy. *N Engl J Med* 335 (1996), 624-630.

(39) Trip, MD, VM Cats, FJ van Capelle, J Vreken: Platelet hyperreactivity and prognosis in survivors of myocardial infarction. *N Engl J Med* 322 (1990), 1549-1554.

(40) Hynes, RO: Integrins: Versatility, Modulation, and Signalling in Cell Adhesion. Cell Vol 69 (1992), 11-25.

(41) Clavete, JJ, Henschen, A, and Gonzalez-Rodriguez, J: Complete localisation of the interchain disulphide bonds and the N-glycosylation points in the α -subunit of human glycoprotein IIb. Biochem J 261 (1989), 561-568.

(42) Clavete, JJ, A Henschen, and J Gonzalez-Rodriguez: Assignment of disulfid bonds in human platelet GPIIIa. A disulphide pattern of the beta-subunits integrin family. Biochem J 274 (1991), 63-71.

(43) Chan, BMC, PD Kassner, JA Schiro, R Beyers, TS Kupper, and ME Hemmler: Distinct cellular functions mediate by different VLA integrin α -subunit cytoplasmatic domains. Cell 68 (1992b), 1051-1060.

(44) Manning, DR, LF Brass: The role of GTP-binding proteins in platelet activation. Thromb Haemost Vol 66 (1991), 393-399.

(45) Shattil, SJ, JS Brugge: Changes in the membrane glycoprotein IIb-IIIa complex and the adhesive function of platelet. Curr Opin Cell Biol 3 (1991), 869-879.

(46) O'Tool, TE, JC Loftus, XP Du, AA Glass, ZM Ruggeri, SJ Shattil, EF Plow, and MH Ginsberg: Affinity modulation of the $\alpha_{IIb}\beta_3$ integrin (platelet GP IIb-IIIa) is an intrinsic propriety of the receptor. Cell Regul 1 (1992a), 883-893.

(47) Du, XP, EF Plow, Frelinger, AL, TE O'Tool, JC Loftus, and MH Ginsberg: Monoclonal antibodies to ligand occupied conformers of integrin $\alpha_{IIb}\beta_3$ (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J Biol Chem 266 (1991), 17106-17111.

(49) Du, XP, EF Plow, AL Frelinger, TE O'Tool, JC Loftus, and MH Ginsberg: Ligand „activate,, integrin $\alpha_{IIb}\beta_3$ (platelet GP IIb-IIIa). Cell 65 (1991), 409-416.

(48) Beak, S, KL March: Gene therapy for Restenosis. Getting nearer to the heart of matter. *Circulation Research* 82 (1998), 295-305.

(50) Erbel, R, M Haude, HW Höppe, C Macaya, M Nobuyoshi, P Probst, M Sigmund, H Emanuelson, B Heubein, W Rutsch, G Hermann, on behalf of the REST Study: Restenosis Study: randomised trial comparing Stenting and balloon angioplasty for treatment of Restenosis after balloon angioplasty. *J Am Coll Cardiol* 27 Suppl A (1996), 139 A.

(51) Bittl, JA: Advances in coronar angioplasty . *N Engl J Med* 335 (1996), 1290-1302.

(52) Newman, PJ, RS Derbes, RH, Aster: The human platelet alloantigens, PI^{A1} and PI^{A2} , are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. *J Clin Invest* 83 (5) (1989), 1778-1781.

(53) Mak, KH, G Belli, SG Ellis, D Moliterno: Subacute stent thrombosis: evolving issues and current concepts. *J Am Coll Cardiol* 27 (1996), 494-503.

(54) Nath, FC, DWM Muller, SG Ellis, U Rosenschein, A Chapetr, L Quain, C Zimmermann, E Topol: Thrombosis of felxible coil sents: frequency, predictors and clinical outcome. *J Am Coll Cardiol* 21 (1993), 622-627.

(55) Neumann FJ, M Gawaz, I Ott, A May, G Mössner, A Schömig: Prospective evaluation of homeostatic predictors of subacute stent thrombosis after coronary Palma-Schatz Stenting. *J Am Coll Cardiol* 27 (1996), 15-21

(56) Ip, JH, V Fuster, D Israel, L Badimon, J Badimon, JH Chesebro: The role of platelets, thrombin, and hyperplasia in Restenosis after coronar angioplasty. *J Am Coll Cardiol* 17 (1991), 77B - 88B.

(57) Le Breton, H, EF Plow, EJ Topol: Role of platelets in restenosis after percutaneous coronary revascularisation. *J Am Coll Cardiol* 28 (1996), 1643-1651.

(58) Makrowitz, JH, GS Roubin, JM Parks, V Bittner: Platelet activation and restenosis after coronary Stenting - flow cytometric detection of wound-induced platelet activation. *Coron Artery Dis* 7 (1996), 657-665.

(59) Casscells, W: Migration of smooth muscle and endothelial cells - critical events in restenosis. *Circulation* 86 (1992), 723-729.

(60) Forrester, JS, M Fishbein, R Helfant, JA Fagin: A paradigm for the restenosis based on cell biology: clues for the development of new preventive therapies. *J Am Coll Cardiol* 17 (1991), 758-769.

(61) Heidland, UE, CJ Michel, MP Heintzen, BE Strauer: Re-Stenose nach PTCA: Pathophysiologische Grundlagen und Möglichkeiten der pharmakologischen und katheterinterventionellen Prävention. *Dtsch med Wsch* 123 (1998), 840-846.

(62) Mintz, GS, JL Popma, AD Pichard, KM Kent, LF Satler, MK Wong, K Mun Hong, JA Kovach, MB Leon: Intravascular ultrasound assessment of the mechanisms and predictors of restenosis following coronar angioplasty. *J Invas Cardiol* 8 (1996), 1-14.

(63) Stone, GW, JM Hodgson, FG St Goar, A Frey, H Mudra, H Sheehan, TJ Linnemeier: improved procedural results of coronary angioplasty with intravascular ultrasound-guided balloon sizing: The COULT Pilot Trial. *Circulation* 95 (1997), 2044-2052.

(64) Ivnahe, RJ, WS Weintraub, JS, F Douglas: percutaneous transluminal coronary angioplasty of chronic occlusions. Primary success, restenosis and long-term clinical-follow-up. *Circulation* 85 (1992), 106-115.

(65) Savage, MP, JS Douglas, DL Fishman for the Saphenus Ven De Novo Trial Investigators: Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. *N Engl J Med* 337 (1997), 740-747.

(66) Gonschior, P, R Wilensky, K March, B Höfling: Lokale Medikamentenapplikations-systeme, präklinische und klinische Anwendung: Perspektiven und Limitationen. *Z Kardiol* 85 (1996), 155-165.

(67) Serruys, PW, BJ Rensing, HE Lutjen, WM Hermans, KJ Beat: Restenosis following coronary angioplasty. In: Meier B. (Ed), *Interventional Cardiology*. Toronto: Hogrefe & Huber: 79-115.

(68) Waller, BF: Crackers, breakers, stretchers, drillers, scrapers, shavers, burners, welders and melters - the future treatment of atherosclerotic coronary artery disease? A clinicalmorphologic assessment. *J Amer Coll Cardiol* 13 (1989), 969-987.

(69) McBride, W, RA Lange, LD Hillis: Restenosis after successful coronary angioplasty. Pathophysiology and prevention. *N Engl J Med* 318 (1988), 1734-1737.

(70) Serruys, PW, WRM Hermans, BJ Rensing and PJ De Feyter: Pharmacological prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA): overawe and methological considerations. Reiber and Serruys (eds), *Advances in Quantitative Coronary Angiography*, (1993), 329-350, Kluwer Academic Publishers, Netherlands.

(71) Ross, R: The pathogenesis of atheroscleritosis - an update. *N Engl J Med* 314 (1986), 488-500.

(72) Liu, MW, Roubin GS, SB King: Restenosis after coronary angioplasty . Potential biologic determinants and role of intimal hyperplasia. *Circulation* 76, (1989), 1374-1387.

(73) Beatt, K. J., P. W. Seruys, P. G. Hugenholtz: Restenosis after coronary angioplasty: new standards for clinical studies. *J. Am. Coll. Cardiol.* 15 (1990), 491-498.

(74) Califf , RM., EM Ohman, DJ Fried, et al.: Restenosis the clinical issues. In: Topol EJ (Ed.) *Textbook in interventional Cardiology*. Philadelphia: Saunders 1990: 343-394.

(75) Gould, KL, K Lipscomb, GW Hamilton: Physiologic basic for assessing critical stenosis: Instantaneous flow response and regional distribution during coronary hyperaemia as measures of coronary flow reserve. *J Am Coll Cardiol* 33 (1974), 87-94.

(76) Nobuyoshi, M, T Kimura, H Nosaka, et al.: Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 299 patients. *J Am Coll Cardiol* 12 (1988), 616-623.

(77) Strauss, BH, MA. M. Morel, EJ Montauben van Swijndregt, WRM Hermans, et al.: The use of quantitative coronary angiography (QCA) in interventional Cardiology. Reiber and Serruys (eds), *Advances in Quantitative Coronary Angiography*, (1993), 397-441, Kluwer Academic Publishers, Netherlands.

(78) de Feyter, PJ, PW Serruys, MJ Davies, P Richardson, J Lubsen, MF Oliver: quantitative coronary angiography to measure progression and regression of coronary atherosclerosis. Value, limitations and implications in clinical trials. *Circulation* 84 (1991), 412-423.

(79) Lefkowski, J, EF Plow, EJ Topol: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. *N Engl J Med* 332 (1995), 1553-1559.

(80) Fitzgerald, D, L Roy, F Catella, G Fitzgerad: Platelet activation in unstable coronary disease. *N Engl J Med* 215 (1986), 983-9.

- (81) Gawaz, MP, JC Löfler, ML Bajt, MM Frojmovic, EF Plow, Ginsberg MH: Ligand binding mediates integrin (platelet GP IIb/IIIa) dependent homotypic and heterotypic cell-cell interactions. *J Clin Invest* 88 (1991), 1128- 1134.
- (82) Phillips, DR, F Charo, RM Scarborough: GpIIb-IIIa: The Responsive Integrin. *Cell* 65 (1991), 359-362.
- (83) D´Souza, SE, MH Ginsberg,TA Bruke, SC-T Lam, EF Plow: Localisation of an Arg-Gly-Asp recognition site within an integrin adhesion receptor. *Science* 242 (1988), 91-93.
- (84) D´Souza, SE, MH Ginsberg,TA Bruke, SC-T Lam, EF Plow: The Ligand binding site of the platelet integrin receptor GpIIb-IIIa is proximal to the second calcium binding domain of alpha subunit. *J Biol Chem* 265 (1990), 3440-3446.
- (85) Charo, IF, L Nannizzi, DR Phillips, MA Hsu, RM. Scarborough: Inhibition of Fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide. *J. Biol. Chem.* 266 (1991), 1415-1421.
- (86) Frelinger, AL, SC-T Lam, EF Plow, MA Smith: Occupancy of an adhesive glycoprotein receptor modulates Expression of an antigenic site involved in cell adhesion. *J Clin Invest* 263 (1988), 12397-12402.
- (87) Yokoi, H, T Kimura, Y Nakagawa, H Nosaka, M Nobuyoshi: Long-term clinical and quantitative angiographic follow-up after the Palmaz-Schatz stent restenosis. *J Am Coll Cardiol* 27 (1996), 224A.
- (88) Nurden, AT: Platelet glycoprotein polymorphism and coronary thrombosis. *Lancet* 350 (1997), 1189-1191.

(89) Epstein, FH: Coronary heart disease epidemiology revisited. Clinical and community aspects. *Circulation* 48 (1973), 185-191.

(90) Hoffmeister, H, GBM. Menssink, H Stolzenberg, J Hoeltz, J Kreuter, U Laser, E Nüssel, KD Hüllmann, J v. Troschke: Reduction of coronary heart disease risk factors in the German Cardiovascular Prevention Study. *Preventiv Med* 25 (1996), 135-145.

(91) Forschungsverbund DHP: Die deutsche Herz-Kreislauf-Präventionsstudie. Verlag Hans Huber, Bern (1998), 149-276.

(92) Hennekens, CH, JE Buring, JE Manson, M Stampfer, B Rosner, NR Cook, C Belanger, F LaMotte, JM Gaziano, PM Ridker, W Willer, R Peto: Lack of effect of long-term supplements with beta carotene on the incidence of malignant neoplasm and cardiovascular diseases. *N Engl J Med* 334 (1996), 1145-1149.

(93) Scheuermann, W, KH Ladwig: Geschlechtsspezifische Unterschiede in Risikofaktoren und Versorgung der koronaren Herzerkrankung. *Z Kardiol* 87 (1998), 528-536.

(94) Baumgart, D, A Schermund, G Görge, M Haude, J Ge, M Adamzik, C Sehnert, K Altmeier, D Grönemeyer, R Seibel, R Ebel: Comparison of electron beam computed tomography with intracoronary ultrasound and coronary angiography for detection of coronary atherosclerosis. *J Am Coll Cardiol* 30 (1997), 57-64.

(95) Detrano, R, T Hsai, S Wang, G Puetes, J Fallavollita, P Shields, W Stanford, C Wolfkiel, D Georgiou, M Budoff, J Reed: Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography. *J Am Coll Cardiol* 27 (1996), 285-290.

(96) Simsek S, NM Faber, PM Bleeker, et al: Determination of human platelet antigen frequencies in the Dutch population by immunophenotyping and DNA (allele-specific restriction enzyme) Analysis. *Blood* 81 (1993), 835-840.

(97) Erbel, R, J Ge, G Geörge, P Kearney, C von Birgelen, A Schwermund, D Baumgarten, R Brennecke, HJ Ruprecht, J Meyer: Intravaskuläre Sonographie bei koronarer Herzkrankheit. Dtsch med Wschr 120 (1995), 847-854.

(98) Falk, E, PK Shah, V Fuster: Coronary plaque disruption. Circulation 92 (1995), 657-671.

(99) Glagov, S, E Weisenberg, CK Zarins, R Stankunavicius, GJ Kolettis: Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316 (1987), 1371-1375.

(100) Bom, N, CT Lancee, FC van Egmond: An ultrasonic intracardiac scanner. Ultrasonic 10 (1972), 72-76.

(101) Nakamura, S, DJ Mahon, B Maheswaran, DE Gutfinger, A Colombo, JM Tobis: An explantation for discrepancy between angiographic and intravascular ultrasound measurement after percutaneous transluminal coronary angioplasty. J Amer Coll Cardiol 25 (1995), 633-639.

(102) Weidinger, F, S Schwarzacher, G Bohm, A Moritz, U Losert, D Glogar: Direct Evaluation of the atherosclerotic arterial wall: Potentials and limitations of intravascular ultrasound. Z Kardiol 81 (1992), 1-8.

(103) Di-Mario, C, SH The, S Madretsma, RJ van-Suylen, RA Wilson, N Bom, P W Serruys, EJ Gussenhofen, JR Roelandt: Detection and characterisation of vascular lesions by intravascular ultrasound : an in vitro Study correlation with histology. J Am Soc Echocardiogr 5 (1992), 135-146.

(104) Görge, G, J Ge, C von Birgelen, R Erbel: Intravaskulärer Ultraschall - Der neue Goldstandard? Z Kardiol 87 (1998), 575-585.

(105) Tam, SH, M. Patricia, BS Sassoli, ER Jordan, T Marian, T Nakada: Abciximab (ReoPro, Chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of Glycoprotein IIb/IIIa and $\alpha v\beta 3$ Integrins. *Circulation* 98 (1998), 1085-1091.

(106) Mascelli, MA, ET Lance, L Damaraju, CL Wagner, HF Weisman, RE Jordan: Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from Gp IIb/IIIa blockade. *Circulation* 97 (1998), 1680-1688.

(107) Schühlen, H, A. Kastrati, J Dirschinger, J Hausleiter, E Shpend, A Wehinger, J Pache, M Hadamitzky, A Schömig: Intracoronary Stenting and the risk for major adverse cardiac events during the first month. *Circulation* 98 (1998), 104-111.

(108) Karrillon, GJ, MC Morice, E Benveniste, P Aubry, S Cattan, B Chevalier, P Commeau, A Cribier, C Eiferman, G.Grollier, Y Guerin, M Henry, T Lefevre, B Livarek, Y Louvard, J Marco, S Markowski, JP Monassier, JM Pernes, P Rioux, C Spaulding, G Zemour: Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French Registry Study. *Circulation* 94 (1996), 1519-1527.

(109) Statistisches Bundesamt, Diagnosestatistik der Krankenhauspatienten 1995 nach ausgewählten Hauptdiagnosen, Alters- und Patientengruppen, Statistisches Bundesamt (Hsg), (1995).

(110) Ridker, PM, JE Buring, J Shih, M Mathias, CH Hennekens: Prospective Study of C-reactive Protein and the risk of future cardiovascular events among apparently healthy women. *Circulation* 98 (1998), 731-733.

(111) Ridker, PM, M Cushman, MJ Stampfer, RP Tracy, CH Hennekens: Plasma concentration of C-reactive Protein and the risk of developing peripheral vascular diseases. *Circulation* 97 (1998), 421-428.

(112) Ridker, PM, M Cushman, MJ Stampfer, RP. Tracy, CH Hennekens: Inflammation, aspirin, and the risk of cardiovascular diseases in apparently healthy men. *N Engl J Med* 336 (1997), 973-979.

(113) Davi, G, I Catalano, M Averano, A Notarbartolo, A Strano, G Ciobottini: Thromboxane biosynthesis and platelet functions in type II diabetes mellitus. *N Engl J Med* 332 (1990), 1769-1774.

(114) Kannel, WB, DL McGee: Diabetes and cardiovascular diseases. The Framingham Study. *J Amer Med Ass* 241 (1979), 2035-2038.

(115) Kornowski, P, GS Mintz, KM, Kent, AD Pichard, LF Sattler, TA Bucher, MK Hong, JJ Popam, MB Leon: Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial ultrasound Study. *Circulation* 95 (1997), 1366-1369.

(116) Aronson D, Z Bloomgarden, EJ Rayfield: Potential mechanism promoting restenosis in diabetic patients. *J Am Coll Cardiol* 27 (1996), 528-535.

(117) Reuter, P: Instabile Angina pectoris - neue Therapiemöglichkeiten durch Gp IIb/IIIa Blocker, 64. Jahrestagung der Deutschen Gesellschaft für Kardiologie - Herz-Kreislaufforschung, Mannheim, April 1998 Kongreßbericht. *Medizin im Dialog* 4 (1998)

(118) Pope, CF, MD Ekzekowitz, EO Smith, S Rapoport, M Glickman, HD Sostman, BL Zaret: Detection of platelet disposition at the site of peripheral balloon angioplasty using iridium-111 platelet scintigraphy. *Am J Cardiol* 55 (1985), 495-497.

(119) Gasperetti, CM, SL Gonias, LW Gimple, ER Powers: Platelet activation during coronary angioplasty in humans. *Circulation* 88 (1993), 2728-2734.

(120) Mintz, GS, JJ Popma, AD Pichard Kent, LF Sattler, MK Hong, J Griffin, MB Leon: Arterial remodelling after coronary angioplasty. A serial intervascular ultrasound Study. *Circulation* 94 (1996), 35-43.

(121) Sigwart, U, J Puel, V Mrkovith, F Joffre, L Kappenberger: Intravascular Stents to prevent occlusion and restenosis after transluminal angioplasty. *N Engl J Med* 316 (1987), 701-706.

(122) Colombo, A, P Hall, A Nakamura, Y Almagor, L Maiello, G Martini, A Gaglione, S Goldberg, J Tobis: Intracoronary Stenting without anticoagulation accomplished with intravascular guidance. *Circulation* 91 (1995), 1676-1688.

(123) Bermejo, J, J Botas, E Gracia, J Elizaga, J Osende, J Soriano, M Abytua, JL Declan: Mechanism of residual lumen stenosis after high-pressure stent implantation. A quantitative coronary angiography and intravascular ultrasound Study. *Circulation* 98 (1998), 112-118.

(124) Komatsu, R, M Ueda, T Naruko, A Kojima, AE Becker: Neointimal tissue response at sites of coronary Stenting in humans. *Circulation* 98 (1998), 224-233.

(125) Daviglius, ML., K Liu, P Greenland, AL Dyer, DB Garside, L Manheim, LP Lowe, M Rodin, J Lubitz, J Stamler: Benefit of a favourable cardiovascular risk-factor profile in middle age with respect to Medicare costs. *N Engl J Med* 339 (1998), 1122-1129.

(126) Gunn, J, and D Cumberland: Does stent design influence restenosis? *European Heart Journal* 20 (1999), 1009-1013.

(127) Frenette, PS, DD Wagner: Molecular medicine adhesions molecules- part 1. *N Engl J Med* 334 (1966), 1526-1529.

(128) Smyth, SS, CC Joneckis, LV Parise: Regulation of vascular Integrins. *Blood* 81 (1993), 2827-2843.

(129) Grimaldi, ChM, F Chen, C Wu, HJ Weiss, BS Coller, DL French: Glycoprotein IIb Leu214Pro mutation produces Glanzmann Thrombasthenia with both quantitative and qualitative abnormalities in Gp IIb/IIIa. *Blood* 91(1998), 1562-1571.

(130) Kleinman, NS., AM. Lincoff, DJ Kereiakes, DP Miller, FV Aguirre, KM Anderson, HF Weismann, RM Califf, EJ Topol, for the EPILOG Investigators: Diabetes, Gp IIb/IIIa Blockade, and Heparin. *Circulation* 97 (1998), 1912-1920.

(131) Strano, A, G Davi, C Patrono: In vivo platelet activation in diabetes mellitus. *Semin Thromb Hemost* 17 (1991), 422-425.

(132) Ip, JH, V Fuster, L Badimon, JJ Badimon, MB Taubman, JH Chesebro: Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell Proliferation. *J Am Coll Cardiol* 15 (1990), 1667 - 1687.

(133) Ruggeri, ZM: von Willebrand factor as a target for antithrombotic intervention. *Circulation* 86 (1992), Suppl III, III-26-III-29.

(134) Hasdai, D, KN Garratt, DE Grill, A Lerman, DR Holmes jr.: Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularisation. *N Engl J Med* 336 (1997), 755-761.

(135) Serruys PW, Luijten HE, Beatt KJ, et al: Incidence of Restenosis after successful coronary angioplasty: a time related phenomena: a quantitative angiographic Study in 342 consecutive patients at 1, 2, 3 and 4 months. *Circulation* 77 (1988), 361-371.

(136) Grüntzig, AR, A Senning, W Siegenthaler: Non-operative Dilatation of coronary artery stenosis. *N Engl J Med* 301 (1979), 61-67.

(137) King, SB, DO Williams, P Chougule, JL Klein, R. Waksman, R Hilstead, J Macdonald, K Anderberg, IR Cocker: Endovascular β -Radiation to reduce restenosis after coronary balloon angioplasty. Results of the Beta Energy Restenosis Trial (BERT). *Circulation* 97 (1998), 2025-2030.

(138) Maching, T, R Zahn, J Rustige, J Gödicke, P Marsalek, D Gulba: Klinische Sicherheit der Anwendung des Thrombozytenaggregationshemmmers c7E3 in der interventionellen Kardiologie bei 520 Patienten. *Z Kardiol* 86 (1997), 975-981.

(139) Libby, P, D Schwartz, E Brogi, H Tanaka, and SK Clinton: A cascade model of restenosis: A special case of atherosclerosis Progression. *Circulation* 86 (1992), Suppl III, III-47-III-52.

(140) Collier, B: Monitoring platelet Gp IIb/IIIa antagonist therapy. *Circulation* 96 (1997), 3825-3832.

(141) Popma, JJ, RM Califf, and EJ Topol: Clinical trials of restenosis after coronary angioplasty. *Circulation* 84 (1991), 1426-1436.

(142) Zimrin, AB, S Gidwitz, S Lord, E Schwarz, JS Bennett, GC Whit 2d, M Poncz: The genomic organisation of platelet glycoprotein IIIa. *J Biol Chem* 265 (1990), 8590-9595.

(143) Mascelli, MA, S Worley, NJ Veriabo, ET Lance, S Mack, T Schaible, HF Weisman, RE Jordan: Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-Gp IIb/IIIa therapy. *Circulation* 96 (1997), 3860-3866.

(144) Davies, MJ: Stability and instability: two faces of coronary atherosclerosis. *Circulation* 94 (1996), 2013-2020.

(145) Schenk, M: Überraschende 10-Jahres-Ergebnisse der MONICA-Studie. Dtsch Med Wsch 123 (1998), A7-A13

(146) Weismann, H: Sieben Länder Studie gibt Auskunft über Risikofaktoren der KHK. Dtsch Med Wsch 123 (1998), A7-A13

(147) Heintzen, MP, CJ Michel, TM Schiele, W Klimek, NK Okasha, RM Klein, BE Strauer: Indikation und Grenzen konventioneller Revaskularisationsverfahren bei der koronaren Herzkrankheit. Z Kardiol 86 (1997), 9-21.

(148) Plow, EF, SE D'Souza, MH Ginsberg: Ligand binding to Gp IIb-IIIa . A native report. Semin Thromb Haemost 18 (1992), 324.

(149) Grewe, PH, A Machraoui, T Deneke, j Barmeyer, KM Müller: Strukturanalyse von 16 verschiedenen Koronarsystemen. Z Kardiol 86 (1997), 990-999.

(150) DeYoung, MB, DA Dichek: Gene therapy for Restenosis. Are we ready? Circ Res 82 (1998), 306-313.

(151) Asakura, M, Y Ueda, S Nanto, A Hirayama, T Adachi, M Kitakaze, M Hori, K Kodama: Remodeling of In-Stent neointima, which became thinner and transparent over 3 years. Circulation 97 (1998), 2003-2006.

(152) Höfling, B, P Gonschior, S Esin, S Nikol: Das Problem der Restenose nach Angioplastie. Klinische Bedeutung, Pathobiologie, zukünftige Entwicklung zur Suppression der Rezidivstenose. Der Internist 38 (1997), 31-43.

(153) Hermans, WRM, BJ Rensnig, BH Strauss, PW Serruys: Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a „magic bullet,„. Am Heart J 122 (1991), 171-187.

(154) Violaris, AG, R Melkert, JPR Herman, PW Serruys: Role of angiographically identifiable Thrombus on long-term luminal renarrowing after coronary angioplasty. A quantitative angiographic Analysis. *Circulation* 93 (1996), 889-897.

(155) Califf, RM, EM Ohman, DJ Frodin, DB Mark, MA Hlatky, JE Bengtson: Restenosis: The clinical issues, in Topol (Ed): *Textbook of Interventional Cardiology*. Philadelphia, WB Saunders Co, 1990, 363-394.

(156) Yamagishi, M, SE Nissen, DC Booth, JC Gurley, J Koyoma, AN DeMaria: Coronary reactivity to nitro-glycerine: intravascular ultrasound evidence for the importance of plaque distribution. *Am J Cardiol* 25 (1995), 224-230.

(157) Mahrholdt, H, KK Haase, A Athanasiadis, B Wullen, A Treusch, A Baumbach, KR Karsch: Vorteile des Einsatzes intravasalen Ultraschalls bei der perkutanen transluminalen Koronarangiographie. *Z Kardiol* 87 (1998), 336-343.

(158) Lehmann, KG, R Melkert, PW Serruys: Contribution of frequency distribution Analysis to the understanding of coronary restenosis. A reappraisal of the gaussian curve. *Circulation* 93 (1996), 1123-1132.

(159) Simonton, CA, MB Leon, DS Baim, T Hinohara, KM Kent, RM Bersin, BH Wilson, GS Mintz, PJ Fitzgerald, PG Yock, J Popma, KKL Ho, DE Cutlip, C Senerchia, RE Kuntz: Optimal directional coronary Atherectomy. Final results of the Optimal Atherectomy Restenosis Study (OARS). *Circulation* 97 (1998), 332-339.

(160) Mudra, H, V Klauss, R Blasini, M Kroetz, J Reiben, E Regar, K Theisen: Ultrasound guidance of Palmaz-Schatz intracoronary Stenting with a combined intravascular ultrasound balloon catheter. *Circulation* 90 (1994), 1252-1261.

(161) Tobis, JM, J Mallery, D Mahon, K Lewhmann, P Zalesky, J Griffith, J Gessert, M Moriouchi, M McRae, ML Dwyer, N Greep, WL Henry: Intravascular ultrasound imaging of human coronary arteries in vivo. *Circulation* 80 (1989), 913-926.

(162) Blankenhorn, DH, PJ Curry: The accuracy of angiography and ultrasound imaging for arteriosclerosis measurement. *Arch Pathol Lab Med* 106 (1982), 483-490.

(163) Nissen, SE, CJ Gurley, CL Grines, DC Booth, R McClure, M Berk, C Fischer, AN DeMaria: Intravascular ultrasound assessment of lumen size and wall morphology in normal subjects and patients with coronary artery disease. *Circulation* 84 (1991), 1087-1099.

(164) Sirois, MG, M Simons, DJ Kuter, RD Rosenberg, ER Edelmann: Rat arterial wall retracts myointimal hyperplastic potential long after arterial injury. *Circulation* 96 (1997), 1291-1298.

(165) Lasne, D, M Krenn, V Pingault, E Arnaud, JN Fiessinger, M Aiach, and F Rendu: Interdonor variability of platelet response to thrombin receptor activation: influence of PI^{A2} polymorphism. *British Journal of Haematology* 99 (1997), 801-807.

(166) Kereiakes, DJ, AM Lincoff, DP Miller, JE Tchong, CF Cabot, KM Anderson, HF Weisman, RM Califf, EJ Topol, for the EPILOG Investigators: Abciximab therapy and unplanned coronary stent deployment. Favorable effects on stent use, clinical Outcomes, and bleeding complications. *Circulation* 97 (1998), 857-864.

(167) Barnhart, JM: Racial variation in the use of coronary-revascularisation procedures. *J Gen Intern Med* 1995; 10S (4): 60. Abstract.

(168) Cooke, GE, PF Bray, JD Hamlington, DM Pham, PJ Goldschmidt-Clermont: PI^{A2} polymorphism and efficacy of aspirin. *Lancet* 351 (1998), 1253.

(169) Herrington, DH: Sources of error in QCA. *Cath Cardiovasc* 23 (1993), 314-321.

(170) Collier, B: Gp IIb/IIIa Antagonists: Pathophysiologic and Therapeutic insights from studies of c7E3 Fab. *Thrombosis and Haemostasis* 78 (1997), 730-735.

(171) Bauriedel, G, R Hutter, S Schluckbier, U Welsch, MF Prescott, R Kandolf, B Lüderitz: Verminderte Apoptose als Pathogenesefaktor der intimale Hyperplasie humaner Arterioskleroseläsionen. *Z Kardiologie* 86 (1997), 572-580.

(172) Dietz, R, J Waigand, F Uhlich, KJ Osterziel, DC Gulba: Stents: Neue Studien – neue Trends. *Z Kardiologie* 86 (1997), 65-69.

(173) Faxon, DP: Visual angiographic readings are more. *J Am Coll Cardiol* 21 (1993), 339A.

(174) Ischinger, T: Should coronary arteries with less than 60% diameter stenosis be treated by angioplasty? *Circulation* 83 (1983), 148-154.

(175) Stiel, M, GK Lund, KP Schanps, A Lattermannz, CA Nienaber: Visuelle Einschätzung oder quantitative Vermessung von Koronarstenosen: Bedeutung für die „prima vista,, PTCA. *Z Kardiologie* 86 (1997), 189-195.

(176) Burke, A, A Farb, GT Malcom, YH Lang, J Smialek, and R Virmani: Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. *N Engl J Med* 336 (1997), 1276-1282.

(177) Lüscher, TF, BS Oemar, Z Yang, G Noll: Molekulare und zelluläre Mechanismen der Arteriosklerose und Restenose: Möglichkeiten der Gentherapie. *Z Kardiologie* 85 (1996), 495-508.

(178) Werner, GS, S Schuenemann, A Knies, KH Scholz, H Kreuzer: Intrakoronare Ultraschallbefunde bei Rekanalisation chronischer Okklusionen: Beziehung zu Restenose und Reokklusion nach Ballonangioplastie oder Stentimplantation. *Z Kardiologie* 87 (1998), 56-66.

(179) Tropel, P, V Roullot, M Vernet, C Poujol, H Pointu, P Nurden, G Marguerie, and D Tronik-Le Roux: A 2,7 kb Portion of the 5' Flanking region of the murine glycoprotein α IIb gene is transcriptionally active in primitive hematopoietic progenitor cells. *Blood* 90 (1997), 2995-3004.

(180) Maguerie, GA, EF Plow: Interaction of Fibrinogen with in platelet receptors. Kinetics and effects of pH and temperature. *Bio Chem* 20 (1981), 1074.

(181) The Capture Investigators: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. *Lancet* 349 (1997), 1429-1435.

(182) Bauriedel, G, B Höfling: Mechanismus der Re-Stenosierung nach Angioplastie. *Medizin im Dialog, Sonderheft Kardiologie*, August 1995, 6-13.

(183) Humpheries, SE, A Thomas, HE Montgomery, F Green, A Winder, G Miller: Gene-environment interaction in the determination of plasma levels of Fibrinogen. *Fibrinolysis and proteolysis* 11 (1997), Suppl 1, 3-7

(184) The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. *N Engl J Med* 330 (1994), 956-961.

(185) Falk, E: Why does plaques rupture? *Circulation* 86 (1992), Suppl III, III32-III-42.

(186) Wencel-Drake, JD, C Bourginon-Poudhon, MG Dieter, AC Criss, and LV Parise: Internalisation of bound Fibrinogen modulates platelet aggregation. *Blood* 87 (1996), 602-612.

(187) Riede, UE, Schäfer HE: Allgemeine und spezielle Pathologie. Georg Thieme Verlag, 4. aktualisierte Auflage, 436-444.

(188) Zotz, RB, BR Winkelmann, M Nauck, G Giers, B Maruhn-Debowski, W März, RE Schäfer: Human platelet antigen 1b (HPA-1b/PI^{A2}) ist ein hereditärer Risikofaktor für den Myokardinfarkt bei koronarer Herzerkrankung. Med Klinik, 93 Band 1 (1998), Poster P-15.

(189) Zotz, RB, R Deitenbeck, ISB Rehtfeld, B Maruhn-Debowski, G Giers, H Bauer, RE Schäfer: Glykoprotein IIb-IIIa-Polymorphismus (HPA-1b/PI^{A2}) ist mit einer vermehrten Bindung an den Plättchen-GPIIb-IIIa-Rezeptor assoziiert. Med Klinik, 93 Band 1 (1998), Poster P-38.

(190) Dick, J, JJ Popma, JW Muller, KA Burek, EJ Topol: In hospitals coast associated with new percutaneous coronary devices. Am J Coll Cardiol 68 (1991), 879-885.

(191) Body, SC: Platelet activation and interactions with the microvasculare. J Cardiovasc Pharmacol 27 (1996), Suppl 13-27.

(192) Kastrati, A, A Schömig, M Seyfert, W Koch, S Elezi, C Böttiger, J Mehilli, K Schömig, N v. Beckerath: PI^A Polymorphism of Platelet Glycoprotein IIIa and Risk of Restenosis After Coronary Stent Placement. Circulation 99 (1999), 1005-1010.

(193) Graboys, T: Coronary angiography; A long look at short queue. JAMA 282 (1999), 184-185.

(194) Coller, BS: Potential non-glycoprotein IIb/IIIa effects of abciximab, Am Heart J Vol 183 (1999), Supplement, Number 1, Part 2, S1-S5.

(195) Droese, K, E Miche, S Eckert, J Vogt, W Lengfelder, U Gleichmann: Bedeutung des intravaskulären Ultraschalls bei angiographisch unterschätztem

Koronarbefund: Darstellung anhand zweier Fallbeispiele. *Z Kardiol* 83 (1997), 857-862.

(196) Sangiorgi, G, AJ Tayler, A Farb, A Carter, W Edwards, DR Holmes, R Virmani: Histopathology of postpercutaneous transluminal coronary angioplasty Remodeling in human coronary arteries. *Am Heart J* 138 (1999), 681-7.

(197) Laule, M, I Cascorbi, V Stangl, C Bieleck, CD Wernecke, PM Morzikiewicz, SB Felix, G Baumann, K Stangl: A1/A2 polymorphism of glycoprotein IIIa and Association with excess procedural risk for coronary catheter interventions: a case controlled Study. *Lancet* 353 (1999), 708-12.

(198) Anderson, J, G King, TL Bair, SP Elmer, JB Muhlenstein, JF Charlquist: Association between a polymorphism in the gene encoding glycoprotein IIa and myocardial infarction or coronary disease. *J Am Coll Cardiol* 33 (1999), 727-33.

(199) Kastrati, A, A Schoemig, M Seyfarth, W Koch, S Elezi, C Boettiger, J Mehilli, K Schoemig, von N Beckrath: P1^A Polymorphism of platelet glycoprotein IIIa and the risk of restenosis after coronary stent placement. *Circulation* 99 (1999), 1005-1010.

(200) Collier, B S: Blockade of platelet gp IIb/IIIa receptors as an antithrombotic strategy. *Circulation* 92 (1995); 2373-2380.

(201) Ware, JA, MT Decenzo, M Smith, M Saitho: Calcium mobilisation and glycoprotein IIb-IIIa complex ligands in epinephrine-stimulated platelets. *The American Physiological Society* 1991, H1619-H1624.

(202) Goodall, AH, N Cruzen , M Panesart, C Hurd, CJ Knight, WH Ouwehands, KM Fox: Increased binding of Fibrinogen to glycoprotein IIIa-Proline33 (HPA-1b, P1^{A2}, Zw^b) positive platelets in patients with cardiovascular disease. *Eur Heart J* 20 (1999); 742-747.

(203) Lincoff, AM, EJ Tchong, RM Califf, DJ Kereiakes, TA Kelly, GC Timmes, NS Kleinmann, JE Booth, C Balog, CF Cabot, KM Anderson, HF Weismann, EJ Topol: Sustained suppression of ischemic complications of coronary intervention by platelet gp IIb/IIIa blockade with abciximab. One year outcome in the EPILOG trial. *Circulation* 99 (1999); 1951-1958.

(204) Bennett, JS, S Zigmond, G Vilaire, ME Cunningham, B Bednar: The platelet cytoskeleton regulates the affinity of the integrin alpha(IIb)beta(3) for Fibrinogen. *J Biol Chem* 27 (1999); 25301-7.

(205) Parise, LV: Integrin alpha(IIb)beta(3) signalling in platelet adhesion and aggregation. *Curr Opin Cell Biol* 1999 Oct, 11(5): 597-601.

(206) Saiki, RK, DH Gelfand, S Stoffel, SJ Scharf, R Higuchi, GT Horn, KB Mullis, Ha Ehrlich: Primer-directed enzymatic amplification of DNA with a thermostable DNA-Polymerase. *Science* 239 (1988), 487-491.

(207) Saiki, RK: Amplifications of genomic DNA. *PCR protocols: A guide to methods and applications*. MA Innis, DH Gelfand, JJ Sninsky, TJ White (Eds.), New York Academic. (1990), 13-20.

(208) Michelson, A, MI Furmann, P Goldschmidt-Clermont, MA Mascelli, C Hendrix, L Coleman, J Hamlington, MR Barnard, T Kicker, DJ Christie, S Kundi, PF Bray: Platelet Gp IIIa PI^{A1/A2} Polymorphism display different sensitivities to agonists. *Circulation* 101 (2000), 1013-1018.

(209) Garasic, JM, ER Edelman, JC Squire, P Seifert, MS Williams, C Rogers: Stent and artery geometry determine intimal Thickening independent of arterial injury. *Circulation* 101 (2000), 812-818.

(210) Finking, G, MH Gohar, C Lenz, H Hanke: Die Wirkung von Östrogen im kardiovaskulären System. *Z Kardiol* 89 (2000), 442-453.

(211) Grewe, PH, T Deneke, SK Holt, A Machraoui, J Barmeyer, KM Müller: Rasterelektronenmikroskopische Analyse der reaktiven und reparativen Veränderungen humaner Koronararterien nach Stentimplantation. Z Kardiol 89 (2000), 21-27.

(212) Danesh, J, J Muri, Y-K Wong, M Ward, JR Gallimore and MB Pepys: Risk factors for coronary heart disease and acute-phase proteins. Eur Heart J 20 (1999), 954-959.

(213) Eeckhout, E, W Wijns, JJ Goy, on behalf of the members of the working group on coronary circulation of the European society of Cardiology. Indication for intracoronary stent placement. Eur Heart J 20 (1999), 1014-1019.

(214) Meier, B: The stent, the procrustes for the chronic total coronary occlusions? Eur Heart J 20 (1999), 1142-1144.

(215) Schiele, F: The "angioplastically correct" follow up strategy after stent implantation. Heart 85(4) (2001), 363-4.

(216) Stryer, L: Biochemie, 4. Auflage, Spektrum Verlag.

(217) Windecker, S, W Maier-Rudolph, T Bonzel, et al: On behalf of the working group Coronary Circulation of the European Society of Cardiology. Interventional Cardiology in Europe 1995. Eur Heart J 20 (1999), 484-95.

(218) Dawber, TR: The Framingham Study: The epidemiologic of arteriosclerotic disease. Cambridge, MA, USA, Harvard University Press, 1980.

(219) Fuster, V, L Badimon, JJ Badimon, JH Chesebro: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326 (1992), 310-318.

(220) Shah, K: Link between infection and atherosclerosis. Who are the culprits: Viruses, bacteria, both, or neither? *Circulation* 103 (2001), 5-7.

(221) Scheller, B, Hennen, B, Pohl, A, Schieffer, Hand T. Markwirth: Acute and subacute stent occlusion. Risk reduction by ionic contrast media. *Eur Heart J* 22 (2001), 385-391.

(222) Orth-Gomér, K: Coronary risk factor modification after the acute event – why are effects not maintained. *Eur Heart J* 22 (2001), 276-279.

(223) Verin, V, Popowski, Y, De Bruyne, B, Baumgart, D, Sauerwein, W, Lins, M, Kovacs, G, Thomas, M, Calmann, F, Disco, C, Serruys, PW, and Willaim Wijns: Endothelium beta therapy for the prevention of coronary restenosis after balloon angioplasty. *N Engl J Med* 344 (2001), 243-249.

(224) Kay, P, Wardeh, A, Kozuma, K, Foley, DP, Knook, M, Thury, A, Sianos, G, van der Giessen, W, Levendag, P, Serruys, PW: Radioactive stents delay but do not prevent in-stent neointimal hyperplasia. *Circulation* 103 (2001),14-17.

(225) Sobel, B: Acceleration of restenosis by diabetes. *Circulation* 103 (2001), 1185.

(226) Van Belle, E, Ketelers, R, Bateurs, C, Périé, M, Abolmaali, K, Richard, F, Labalanche JM, McFadden, E, Bertrand, M: Patency of percutaneous transluminal coronary angioplasty sites at 6 month angiographic follow up. *Circulation* 103 (2001),1218.

(227) Al Suwaidi, J, Berger, PB, Holmes, DR: Coronary artery stents. *JAMA* 284 (2000), 1828-36.

(228) Nissen, E, and Yock, P: Intravascular ultrasound. *Circulation* 103 (2001), 604-616.

(229) Brenner, DJ, Miller, RC: Long term efficacy of intracoronary irradiation in inhibiting in-stent restenosis. *Circulation* 103 (2001),1330.

(230) Da Li Feng, Lindpainter, K, Larson M, O'Donnell. Lipinska, I, Sutherland, P, Mittelmann, M, Muller, JE, D'Agostino, R, Levy, D, Tofler, GH: Platelet glycoprotein IIIa P1^A polymorphism, fibrinogen, and platelet aggregability. The Framingham Heart Study. *Circulation* 104 (2001); 140-144.